The World Authority For Unbiased Longevity News™️

Subscribe Today!

Our Mission: SuperAging™
(n.) Using new medical science and biohacking to slow down the aging process, repair existing damage and live a dramatically longer life in peak physical and mental health.

Credit: https://longevity.technology/news/the-state-of-longevity-new-biotech-companies-emerging-from-stealth/

Four Promising Biotech Companies Back in the Spotlight

March 3, 2022

  • Four noteworthy companies have emerged from stealth with promising results and new directions for research. 
  • Companies include biotherapeutic developers, nutraceutical manufacturers, and a preclinical drug discovery company. 
  • Researchers hope to solve problems related to the limited effectiveness of gene therapies, slow aging through dietary supplements, disrupt the drug-discovery research structure, and open up new doors for human gut biome research. 
Throughout 2021, several biotech longevity companies came out of stealth and revealed their projects to interested parties. Below are some notable biotech companies that announced their research direction in 2021.  Current gene therapies have shown impressive results, but drawbacks are present in today’s therapies. Capsida Biotherapeutics aims to address these. Gene therapies struggle with precision targeting and limited effectiveness in transducing therapeutic gene products. Generally, gene therapies need to be administered at higher doses and frequencies. Capsida is tackling these concerns with an AAV engineering platform to improve specificity, improve safety and effectiveness.  NOVOS is a start-up producing science-based nutraceuticals. Launching in January 2021, NOVOS Core is the company’s mix-and-drink nutraceutical powder containing a patent-pending formula designed to slow aging. NOVOS selected ingredients that were supported by empirical research to slow aging and extend the lifespan. NOVOS also plans to offer its customers access to novel longevity tests, such as facial AI tests and epigenetic panels. NOVOS secured over $3 million of pre-seed financing in 2021.  Cambrian Biopharma operates as a hub for a family of companies, assembling teams of experts in fields like novel drug development, clinical trials, finance, and market analysis. Cambrian refers to this model as a DisCo, or a distributed drug discovery company. Cambrian has identified three priorities. The company aims to address intracellular, cellular, and tissue-level dysfunction. At the intracellular level, the company is focused on issues that impact specific cellular systems. The cellular level is concerned with whole-cell problems, and the tissue level is concerned with dysfunctions of tissues and organs.  Wild Biotech recently emerged from stealth after collecting a database of over 1,200 gut bacteria. Wild Biotech from dozens of animals, and 75% of the bacterial species were previously unknown. Their research opens up thousands of new research pathways for autoimmune diseases. Wild Biotech’s funding has not been disclosed.  Credit: https://longevity.technology/news/the-state-of-longevity-new-biotech-companies-emerging-from-stealth/ 

References: https://longevity.technology/news/the-state-of-longevity-new-biotech-companies-emerging-from-stealth/

Share Your Thoughts

Your email address will not be published. Required fields are marked *

Copyright © 2022 LongevityAge